Drug
placebo vaginal tablet
placebo vaginal tablet is a pharmaceutical drug with 4 clinical trials. Historical success rate of 75.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
75.0%
Based on 3 completed trials
Completion Rate
75%(3/4)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(25%)
Phase Distribution
Ph phase_1
1
25%
Ph phase_3
1
25%
Ph phase_4
1
25%
Ph phase_2
1
25%
Phase Distribution
1
Early Stage
1
Mid Stage
2
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
1(25.0%)
Phase 3Large-scale testing
1(25.0%)
Phase 4Post-market surveillance
1(25.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
75.0%
3 of 4 finished
Non-Completion Rate
25.0%
1 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(3)
Terminated(1)
Detailed Status
Completed3
Terminated1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
75.0%
Most Advanced
Phase 4
Trials by Phase
Phase 11 (25.0%)
Phase 21 (25.0%)
Phase 31 (25.0%)
Phase 41 (25.0%)
Trials by Status
terminated125%
completed375%
Recent Activity
0 active trials
Showing 4 of 4
completedphase_3
Vaginal Dinoprostone Administration Prior to a T380A Intrauterine Device Insertion in Nulliparous Women.
NCT03686085
completedphase_4
Vaginal Dinoprostone Prior to Diagnostic Office Hysteroscopy in Postmenopausal Patients
NCT03683914
terminatedphase_2
Efficacy and Safety Study of Rifaximin Vaginal Tablets in Bacterial Vaginosis
NCT02376972
completedphase_1
Safety, Pharmacokinetics, Pharmacodynamics, and Disintegration Time of Vaginal Tablets Containing Tenofovir and/or Emtricitabine
NCT01694407
Clinical Trials (4)
Showing 4 of 4 trials
NCT03686085Phase 3
Vaginal Dinoprostone Administration Prior to a T380A Intrauterine Device Insertion in Nulliparous Women.
NCT03683914Phase 4
Vaginal Dinoprostone Prior to Diagnostic Office Hysteroscopy in Postmenopausal Patients
NCT02376972Phase 2
Efficacy and Safety Study of Rifaximin Vaginal Tablets in Bacterial Vaginosis
NCT01694407Phase 1
Safety, Pharmacokinetics, Pharmacodynamics, and Disintegration Time of Vaginal Tablets Containing Tenofovir and/or Emtricitabine
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4